Alpha Tau Medical (DRTS) said Monday the US Food and Drug Administration approved an investigational device exemption supplement for its Alpha DaRT radiation therapy.
The supplement allows for the expansion of the study examining the combination of Alpha DaRT and first-line chemotherapy to include both newly diagnosed metastatic and locally advanced pancreatic cancer patients, increasing the total number of patients to 30 across two cohorts, according to the company.
Shares of Alpha Tau Medical were down 1.6% in recent trading.
Price: 3.64, Change: -0.06, Percent Change: -1.62
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。